Operational improvement stands out in RPG Life Science’s Q4 earnings.
CT Renganathan, MD of RPG Life Sciences, said, “The domestic market is the largest contributing business for us. It is contributing close to around 60 percent of our business and remaining 35-40% comes from international.”
“Oncology is relatively a new business for us. We were doing around Rs 10-11 crore a year. As a company, we are looking at oncology as a long-term commitment by having a better antibody strategy. Down the line, three-four years, it should give around Rs 60-80 crore,” he added.